Singulair Allergy Approval Will Drive Sales Despite OTC Claritin, Merck Says
Executive Summary
Merck's Singulair allergic rhinitis indication will help accelerate growth for the asthma drug in 2003, despite the onset of OTC Claritin, Investor Relations Senior Director Mark Stejbach told investors on a Dec. 5 conference call
You may also be interested in...
Merck Singulair Presents Managed Care Test: Covering Asthma, Not Allergies
Merck's Singulair approval in allergic rhinitis presents a challenge for managed care to differentiate between the drug's existing asthma indication and its use in allergies when making coverage decisions
Merck Singulair Presents Managed Care Test: Covering Asthma, Not Allergies
Merck's Singulair approval in allergic rhinitis presents a challenge for managed care to differentiate between the drug's existing asthma indication and its use in allergies when making coverage decisions
Medicare Rx Positioning For 2003: Merck Prepares Investors For Benefit
Merck is telling investors to expect a "meaningful" Medicare prescription drug benefit in the 108th Congress